Filing Details
- Accession Number:
- 0001209191-19-049231
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-09-11 19:19:29
- Reporting Period:
- 2019-09-09
- Accepted Time:
- 2019-09-11 19:19:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1758494 | Alejandro Eric Miller | C/O Acadia Pharmaceuticals Inc. 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 | Controller & Pao | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-09-09 | 7,500 | $20.65 | 12,145 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-09-09 | 3,900 | $32.28 | 16,045 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-09-09 | 6,063 | $29.24 | 22,108 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-09-09 | 4,439 | $36.54 | 26,547 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-09-09 | 4,593 | $35.80 | 31,140 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-09-09 | 1,972 | $16.50 | 33,112 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-09-09 | 28,467 | $39.49 | 4,645 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-09-11 | 4,645 | $41.18 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-09-09 | 7,500 | $0.00 | 7,500 | $20.65 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-09-09 | 3,900 | $0.00 | 3,900 | $32.28 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-09-09 | 6,063 | $0.00 | 6,063 | $29.24 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-09-09 | 4,439 | $0.00 | 4,439 | $36.54 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-09-09 | 4,593 | $0.00 | 4,593 | $35.80 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-09-09 | 1,972 | $0.00 | 1,972 | $16.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-05-29 | No | 4 | M | Direct | |
| 0 | 2025-01-25 | No | 4 | M | Direct | |
| 552 | 2026-01-05 | No | 4 | M | Direct | |
| 2,911 | 2027-03-07 | No | 4 | M | Direct | |
| 4,594 | 2027-09-06 | No | 4 | M | Direct | |
| 3,598 | 2028-04-06 | No | 4 | M | Direct |
Footnotes
- Includes 860 shares of the Issuer's common stock acquired by the reporting person on November 15, 2018 and 573 shares of the Issuer's common stock acquired by the reporting person on May 15, 2019 pursuant to an employee stock purchase program.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.49 to $39.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.1401 to $41.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The option is fully vested and exercisable.
- 25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2017, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the Stock Option vested and became exercisable on March 8, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
